Artificial insemination is a medically assisted reproduction technique commonly used to overcome fertility issues in both humans and livestock. The procedure involves collecting semen samples from males and then introducing them into the female's uterus or fallopian tubes at the time of ovulation to facilitate fertilization. In humans, it is often used as a first-line treatment for cervical factor infertility and as a less expensive first-tier treatment prior to in vitro fertilization. It allows for the use of donor sperm in helping single and lesbian women to conceive.

The global artificial insemination market is estimated to be valued at US$ 10.6 Mn in 2024 and is expected to exhibit a CAGR of 8.1% over the forecast period 2024 to 2031, as highlighted in a new report published by Coherent Market Insights.

Market Dynamics:

Rising infertility rates worldwide due to rising stress levels, lifestyle changes, obesity, and increasing trend of late pregnancies among women are driving the growth of the artificial insemination market. According to the National Survey of Family Growth (NSFG), in 2015-2017 around 6.7% of married women aged 15-49 years in the U.S. were unable to get pregnant after 1 year of trying. These infertility rates create high demand for fertility treatment options including artificial insemination. Additionally, increasing acceptance of same-sex marriage and relationships along with the desire to start a family is also boosting the demand for artificial insemination procedures performed with donor sperms. Moreover, technological advancements in artificial insemination such as intrauterine insemination and intracytoplasmic sperm injection are aiding their increasing adoption rates. However, risks associated with these procedures along with higher cost compared to natural conception are some of the factors expected to hamper market growth over the forecast period.

SWOT Analysis

Strength: Artificial insemination is a widely available and well established technology with low costs compared to other assisted reproductive technologies. The procedure is minimally invasive for patients. It reduces health risks for patients with genetic disorders by avoiding sexual intercourse.

Weakness: Artificial insemination relies on the quality and availability of donor sperm, eggs or embryos which can be limited in some regions. The procedure does not guarantee pregnancy and may require multiple attempts adding physical and emotional burden on patients.

Opportunity: Rising infertility rates globally due increasing stress levels, pollution levels, lifestyle changes are driving the demand for fertility services. Advancements in cryopreservation techniques are improving the storage and transportation of genetic material expanding the donor pools.

Threats: Regulations surrounding donor compensation and anonymity varies significantly across regions introducing commercial and ethical challenges. Alternative fertility procedures like in-vitro fertilization (IVF) offers higher success rates per cycle reducing the appeal of artificial insemination.

Key Takeaways

The global Artificial Insemination Market Demand is expected to witness high growth over the forecast period until 2031 supported by rising infertility prevalence and increasing acceptance of advanced reproductive technologies. The global artificial insemination market is estimated to be valued at US$ 10.6 Mn in 2024 and is expected to exhibit a CAGR of 8.1% over the forecast period 2024 to 2031.

Regional analysis

North America dominates the global market supported by well-developed healthcare infrastructure, availability of advanced fertility clinics and higher medical expenditures. The U.S. accounts for the largest share in the region. However, Asia Pacific is expected to witness fastest growth led by China and India where affordability of AI procedures has improved access to treatments. Growing medical tourism and emergence of low-cost IVF clinics in these regions are major drivers.

Key players

Key players operating in the artificial insemination market include Pride Angel, Irvine Scientific, Hi-Tech Solutions, Rinovum Women’s Health, LLC, TenderNeeds Fertility, Conceivex, Inc., Labotech GmbH, Hamilton Throne Ltd., Biogenics Inc., Nikon Instruments Inc., Zander scientific Inc., and Surelife Pte Ltd. These established companies invest heavily in expanding product portfolios and geographic presence through mergers and acquisitions to gain leadership positions in the lucrative market.

Explore more related articles: